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Abstract Migraine with and without aura (MA and MO,
respectively) have a strong genetic basis. Different approa-
ches using linkage-, candidate gene- and genome-wide
association studies have been explored, yielding limited
results. This may indicate that the genetic component in
migraine is due to rare variants; capturing these will require
more detailed sequencing in order to be discovered. Next-
generation sequencing (NGS) techniques such as whole
exome and whole genome sequencing have been successful
in finding genes in especially monogenic disorders. As the
molecular genetics research progresses, the technology will
follow, rendering these approaches more applicable in the
search for causative migraine genes in MO and MA. To date,
no studies using NGS in migraine genetics have been pub-
lished. In order to gain insight into the future possibilities of
migraine genetics, we have looked at NGS studies in other
diseases and have interviewed three experts in the field of
genetics and complex traits. The experts’ ideas suggest that
the preferred NGS approach depends on the expected effect
size and the frequency of the variants of interest. Family-
specific variants can be found by sequencing a small number
of individuals, while a large number of unrelated cases are
needed to find common and rare variants. NGS is currently
hampered by high cost and technical problems concurrent
with analyzing large amounts of data generated, especially
by whole genome sequencing. As genome-wide association
chips, exome sequencing and whole genome sequencing
gradually become more affordable, these approaches will be
used on a larger scale. This may reveal new risk variants in
migraine which may offer previously unsuspected biological
insights.
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Introduction
Migraine is an episodic and disabling neurological disorder
affecting roughly 14 % of the population [1]. The two most
prevalent forms are migraine without aura (MO) and
migraine with aura (MA) [2]. Migraine tends to run in
families and has a strong genetic basis, with heritability
estimates of 40–57 % [3–5]. In the rare monogenic subtype
of migraine, familial hemiplegic migraine (FHM), three
causative genes have been identified [6–8]. There is,
however, no significant association between these genes
and MO and/or MA [9]. Many linkage studies and candi-
date gene studies have suggested causative genes in MO
and MA, but few have been replicated. Recent attempts
using genome-wide association studies (GWAS) have
yielded four single nucleotide polymorphisms (SNPs) that
are significantly associated with migraine and recently,
three additional SNPs have shown convincing association
as well [10–12]. Nevertheless, only a small part of the
genetic background of MA and MO has been established.
This lack of success in migraine genetics depends on
several factors: the heterogeneity of the migraine disease,
the lack of a quantitative phenotype and the fact that not all
variants associated with migraine have been discovered.
There may also be rare variants which cannot be captured
by the methods used so far [13, 14].
The field of molecular genetics is developing rapidly
and may now have reached a point where gene finding
problems can be overcome in MO and MA. The most
important new methods that are relevant for MO and MA
are commonly termed next-generation sequencing (NGS).
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Explicitly, NGS consists of whole exome sequencing (WES)
and whole genome sequencing (WGS). To date, no studies
using NGS methods in studies of migraine have been
published.
The aim of the present study is, in the first part, to give a
brief overview of the current knowledge of migraine genet-
ics, and to introduce the new emerging molecular genetics
techniques and their use in future genetic migraine research.
This study does not provide a systematic review or a com-
plete overview of the existing literature, as others have
recently done this. The second part of our study is based on
interviews with three genetic experts, because the genetic
field is developing much faster than the literature. The
experts offer their perspectives on the future of migraine
genetics and we present here a summary of their main ideas.
Background and overview of previous genetic
migraine studies
Linkage and candidate gene studies
Linkage studies are family-based and have been widely
used in the search for susceptibility genes in MA and MO.
This strategy is robust in identifying highly penetrant
variants, such as genes of large effect in Mendelian dis-
eases. In complex disorders caused by multiple genes,
linkage studies have yielded poorer results [15]. The can-
didate gene approach is based on a case–control design and
does not involve an analysis of large family pedigrees.
Candidate gene studies depend on prior knowledge of a
few selected genes, based on evidence from linkage studies
or prior knowledge of the function of the gene of interest
[16]. Several linkage studies have found loci with strong
evidence of linkage to migraine with and without aura, and
candidate gene studies have resulted in positive associa-
tions. However, most of the studies have been underpow-
ered and for the main part, replication studies have not
been done, or the replicated results have not been statisti-
cally significant (reviewed in [17, 18]). There might be
several reasons for this limited success. One of the expla-
nations is that the rare family-specific variants have a
significant impact within subsets of families and these
might not be replicated in other families or case–control
studies. Due to this, results from different family studies
will contradict each other and the susceptibility to migraine
that these variants account for can be questioned [19].
Genome-wide association studies
Genome-wide association studies have been the preferred
method in the last few years. This approach is also based
on a case–control design, but compared to the previous
methods, GWAS is a non-hypothesis driven method.
GWAS rely on the common disease-common variant
model, stating that most of the genetic variation in common
complex diseases is due to common variants [20, 21].
Four significant SNPs have been associated with MA
and/or MO. In a recent GWAS, three additional SNPs have
been convincingly associated with MO only [10–12]. The
first GWAS was performed by the International Headache
Genetics Consortium in a clinical-based population and
identified the first SNP associated with migraine. The
variant marker (rs1835740) is located on chromosome
8q22.1 between two potential candidate genes involved in
glutamate homeostasis [10]. In the second migraine GWAS
by Lighardt et al., different population-based cohorts were
pooled together and resulted in large migraine cohorts both
for the original sample and for the replication sample.
Despite this, none of the SNPs investigated reached the
genome-wide significant threshold [22]. In the third
GWAS, three additional SNPs were found to be associated
with migraine. The three variants identified were located
on the chromosomes 2q37.1, 12q13.3 and 1p36.32 in
regions of genes involved in glutamate homeostasis and
pain mechanisms [11]. Recently, Freilinger et al. reported a
GWAS where three SNPs were convincingly associated
with MO. Two of the SNPs were located at 1q22 within the
MEF2D gene, which regulates neuronal differentiation and
restricts the number of excitatory synapses by neuronal
activity-dependent activity. The third SNP was located
close to the TGFBR2 gene at chromosome 3p24. This gene
encodes a serine-threonine kinase, which is involved in the
regulation of cell proliferation and differentiation and in
the production of extracellular matrix. Two more suscep-
tibility loci were found in the study. However, the repli-
cation of these was weak and further studies are needed
[12]. All the aforementioned associations conferred only a
small increase in risk, yielding odds ratios (OR) not higher
than 1.36 [10–12].
Cox et al. recently did a pedigree-based GWAS in
relation to migraine. They studied an isolated population of
Norfolk Island with a high prevalence of migraine and
found associations of SNPs within genes of the serotonin-
ergic system. The associations might be specific for this
isolated population, but might bring insights and inspira-
tion to future research [23].
It is evident that common variants are not solely
responsible for the disease phenotype, and that a proportion
of the genetic predisposition will be explained by highly
penetrant rare variants. These rare variants will not be
captured with GWAS [13].
One of the disadvantages of GWAS is the subsequent
work required to confirm that the identified SNPs are caus-
ally related to migraine and to verify that genes in the vicinity
of the SNP are implicated in migraine pathogenesis. Hence,
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the identification of a variant does not mean that the causa-
tive gene has been found. On the contrary, the variant is often
located in non-coding regions many kilobases away from a
gene. Finding the causative gene may thus require tremen-
dous work first, by fine mapping the genomic area of interest
and then by performing functional studies [13, 14, 24].
Next-generation sequencing
A GWAS using 600,000 markers can give a sufficient
sample size and reveal common variants with a population
frequency down to 5 %. To reveal variants with a popu-
lation frequency lower than 5 %, more markers and new
technologies are required. If a GWAS with 1 million
markers is used in large samples combined with the
imputing of un-genotyped markers, it is possible to capture
most of the genetic variation down to a population fre-
quency of 1–2 % [25]. This would allow new migraine
variants to be discovered [25]. In order to find very rare
variants with a population frequency\1 %, it is necessary
to perform exome or WGS. These methods are commonly
referred to as NGS [13]. The NGS approaches are expen-
sive and complicated to analyze, but with the current
advances in bioinformatic they are becoming feasible. To
date, no migraine genetic studies using NGS methods have
been published.
Whole exome sequencing
Whole exome sequencing is an investigation of the nucleo-
tide sequence in the protein coding regions, the exons. The
exons constitute approximately 1 % of the human genome
[26]. Knowledge from Mendelian disorders indicates that
most of the causal mutations in monogenic diseases are
found in the coding regions of the genome [27]. The coding
regions may, however, also be a good source of rare muta-
tions in complex diseases, such as migraine.
Due to the cost, early exome sequencing efforts were
limited to the sequencing of a few individuals. WES has been
efficient in finding de novo mutations in sporadic cases of
disease by sequencing parent–child trios, in which only the
offspring was affected. This approach is effective for
monogenic disorders, but has also been used for complex
traits such as autism, mental retardation and schizophrenia
[28–30]. Although these diseases are genetically and phe-
notypically heterogeneous, and may be caused by mutations
in several genes, knowledge of mutations with large effect in
sporadic cases can be used to identify candidate genes and to
provide knowledge of disease pathogenesis [28, 31].
Some of the benefits of WES are that in a single
experiment nearly all the coding regions likely to contain
most of the disease-causing mutations can be assayed. It is
possible to identify a single or a few variants that are causal
for the phenotype of interest, and to identify genes acting in
pathways previously unknown. Experiences with WES
from other diseases illustrate how new disease insight can
be gained through this approach; some mutations causing
autism are found in genes that are previously found to be
involved in intellectual disability or epilepsy. This shows
how one pathway may lead to different phenotypes by
interaction with other factors, such as the environment
[29]. Current WES methods are especially useful for
identification of disease-causing variants in a single large
family. There are still some remaining challenges for the
usage of WES in large-scale case–control studies, in par-
ticular the high sequencing price combined with the need
for big sample sizes. The latter can be exemplified by a
recent exome sequencing study where a variant related to
amyotrophic lateral sclerosis (ALS) was identified. The
variant was found in a four-generation Italian family, in
which four family members were diagnosed with ALS.
Subsequent analysis demonstrated that the same variant
was present in 1–2 % of a large cohort of familial ALS
cases from unrelated families [32]. This study emphasizes
the fact that this mutation only influences a small propor-
tion of the disease phenotype. In order to find this rare
mutation with significant reproducible results, many family
members and matched controls are necessary.
The cost of WES is not the only limitation of this
technique. Before the DNA is sequenced, it is cut into
small fragments that facilitate the reading process. How-
ever, this results in difficulty when the origin of a
sequencing fragment is to be found [33]. In addition, the
current methods provide data of varying depth across the
exomes, which might result in a capturing bias [34]. WES
is not effective in capturing all mutation mechanisms;
structural variants such as repetitive regions are likely to be
missed and these might play an important role in some
diseases [33]. Finally, an important limitation is that causal
variants in non-coding areas are missed. To capture these,
sequencing of the whole genome is necessary [26, 27].
In addition to these sequencing limitations, a challenge
in relation to the use of WES in case–control studies for
complex diseases will be to identify rare causal variants in
unrelated cases. These variants will, due to their rarity, not
be shared by all affected individuals. How to point out
these variants as causes of disease remains challenging and
the exact migraine sub-diagnose of each individual is of
great importance [35].
Despite the limitation, WES is being used in a larger
setting. A project named ‘‘The 1000 Genome Project’’ aims
to identify nearly all variants that exist at any appreciable
frequency in different populations using WES. These
variants catalogued in the 1000 Genome Project can be
used for the selection of SNPs to be used on next-genera-
tion GWAS chips [25].
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Whole genome sequencing
From the whole exome sequencing, the next step is WGS.
This approach is costly, and complicated by massive
analysis of the enormous amounts of data generated in this
high-output method. Furthermore, it is currently difficult to
distinguish true variants from sequencing errors. A lot of
work is devoted to the development of analysis techniques
that can cope with the millions of variants emerging and
combine data from different variants into one analysis [36].
Whole genome sequencing has confirmed single-gene
variants in families with rare diseases such as Charcot–
Marie–Tooth and severe hypercholesterolemia [37, 38].
Altogether, published studies of WGS are scarce. The
benefit of WGS is that the whole genome is sequenced, not
just the coding regions and the regions we already know as
functional. The structural variants that were likely to be
missed by WES are more likely to be captured by WGS.
The limitations and challenges of WGS are very much the
same as mentioned for WES, as they are based on the same
sequencing technology [33]. However, using current tech-
nologies, sequencing the whole genome may result in
lower depth of coverage compared to exome sequencing
[39]. The analysis is further complicated by a higher error
rate and uncertainty about how allele frequencies of pre-
viously unknown SNPs should be estimated [36, 40].
Despite this, the most limiting factor for WGS is probably
the cost. Again, as the price of this method decreases, the
use of WGS may increase in the near future [41].
The experts’ perspective
Migraine genetic research has shown to be challenging.
A mix of different techniques and approaches are required
to solve the genetic questions. First, an important factor to
consider when looking at migraine is the effect size of the
causative variants. In familial migraine, the effect size will
be high but in sporadic migraine, the effect size will be
smaller. It is not clear, how big an effect size is required in
order to define familial migraine. The study design depends
on the effect size of the variants of interest. GWAS finds
common variants (with a population frequency down to
5 %) with relatively small effect size and requires a large
number of unrelated cases to provide significant results,
whereas exome sequencing and WGS might be more
suitable in capturing rare variants with a high effect size by
sequencing a small numbers of individuals (Fig. 1).
It is possible to combine the different approaches by the
imputation of WGS data into pedigrees where GWAS data
are already known. This method is especially well-suited in
Iceland due to its founder population characterized by long
haplotypes (a set of SNPs that tend to be inherited together),
and the availability of extensive genealogy information of its
inhabitants in the large pedigree database ‘‘I´slendingabo´k’’.
Furthermore, in Iceland GWAS has already been completed
on tens of thousands of inhabitants using a chip containing
approximately 600.000 variants. Some of the genotyped
Icelanders have undergone a mid-depth WGS, and a haplo-
type can then be created by imputing the WGS data into the
chip-genotyped information. Such founder populations are
ideal for the purpose of finding mutations. The discovered
mutation can afterwards be investigated for a disease-caus-
ing role in more outbred populations.
In regard to familial migraine molecular genetics,
studies performed successfully in other complex disorders
(e.g., familial diabetes or obesity) may be a source of
inspiration for future migraine genetic research. In familial
disease, exome sequencing has been performed in the
person with the disease, the parents (where one is affected
and the other parent is not) and another distantly related
affected person. With this design, the mutation is assumed
to be autosomal dominant. After the exomes of these four
cases have been sequenced, many individual variants are
expected to be found. The next step is to reduce the number
of variants by filtering. The first filters applied are variants
taken from the HapMap (a database cataloguing all known
SNPs in the human genome [42]) or the 1000 Genome
Project, since these variants are not associated with severe
disease phenotypes. The next filter is population-specific
exome data, because some variants occur only in certain
sub-populations and are not disease-causing. After filtering,
the remaining variants may be reduced to a few family-
specific variants, which are thereafter tested for segregation
within the whole family. The idea is that the affected
family members should have the variant(s), while it should
be absent in the healthy family members. In the end, this
approach will yield a few or at best one variant. The pro-
cess is summarized in Fig. 2. Using this design, it may
suffice to examine one big family with ten or more affected
individuals. These variants are likely to be family-specific
and will not be found by GWAS. In cases where no
strongly associated variant is found, it is assumed that the
variant is not located in the coding regions, and these
families become suitable candidates for WGS, when this
method becomes more available.
The use of WES and WGS is still not without its limi-
tations, such as high error rates and challenges in analyzing
data. However, in the genetic research of psychiatric dis-
orders, it has been possible to avoid the analysis problems
by focusing on a specific region. One vulnerable area
associated with a wide spectrum of psychiatric conditions
has been identified and WGS focusing on this area only is
being carried out. This strategy requires a pre-existing
knowledge of a locus of interest which currently does not
exist in migraine.
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While the focus has been on the novel sequencing
techniques, GWAS has expanded its use and possibilities
with new chips containing more SNPs. This is referred to
as next-generation GWAS [43]. With this approach,
variants down to a population frequency of 1 % are found.
Due to the large number of SNPs tested simultaneously in
GWAS, the usual statistical level of 0.05 is too lenient and
will result in thousands of false positive results. Therefore,
the genome-wide significant level is set at 5 9 10-8, which
is based on the testing of 1 million SNPs [44]. In rare
variants, however, less than 1 % of the population carries
the variant and it may therefore be necessary to test even
more SNPs, requiring the genome-wide significance
threshold to be lowered to at least 5 9 10-9. Thus, large
sample sizes and collaboration between multiple research
centers in consortia will be necessary.
All the mentioned approaches can be applied to
migraine according to the effect size of the variants of
interest. WES and WGS will be suitable in finding family-
specific migraine variants, while the next-generation
GWAS will be the best method in sporadic migraine cases.
Currently, it is feasible to perform WES or WGS in
familial migraine cases by testing if the identified variants
segregate in the family. The findings should thereafter be
replicated in other migraine families. Results from founder
populations might give valuable insights and inspiration for
future migraine genetic research. Combining all the results
from common, rare and family-specific variants will
greatly improve our knowledge and understanding of the
migraine disease.
The NGS may explain some of the missing heritability,
but part of the heritability is likely to be explained by other
mechanisms such as gene–gene interactions, gene–envi-
ronment interactions and epigenetics (changes in the
Fig. 1 The sequencing
technique of choice in relation
to the effect size and the
population frequency of the
variants. To find common (with
a population frequency down to
5 %) and rare variants
(population frequency of
1–2 %) with small effect size,
many individuals are required
while family-specific variants
can be found by sequencing few
individuals. Adapted from
McCarthy et al. [44]
Exome sequencing of 4 
family members
Filter common variants 
from HapMap and 1000 
Genome Project
Filter population specific 
variants from already 
existing data
Test if the affected family 
members have the variant 
and the unaffected do not
Few/one variant left
Fig. 2 Strategy for finding variants in cases with family segregation
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disease or in the gene expression caused by mechanisms
other than changes in the underlying DNA sequence [45]).
These factors may play a role, but the mechanisms still
need to be understood, which cannot be done by
sequencing alone. The epigenetic factor is mentioned in a
recent review by Bras et al., where speculations about the
role of methylation of the genome are raised, as well as the
role of gene–environment interactions. Bras et al. [33]
underline the need of simultaneous study of DNA, RNA
and protein to completely understand the genetic back-
ground of disease mechanisms.
Conclusion
We have presented a brief overview of the genetic litera-
ture and interviewed genetic experts. The future of
migraine genetics has a lot of potential. As genome-wide
association chips, exome sequencing and WGS become
more affordable, these techniques will be used on a larger
scale. This may reveal new risk variants in migraine and
offer new pathophysiological insights.
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